Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Atchison, CJ; Lopman, BA; Harris, CJ; Tam, CC; Iturriza Gómara, M; Gray, JJ (2009)
Publisher: European Centre for Disease Prevention and Control
Languages: English
Types: Article

Classified by OpenAIRE into

mesheuropmc: virus diseases, fluids and secretions, viruses
: Two rotavirus vaccines have recently been licensed in Europe. Rotavirus surveillance data in many European countries are based on reports of laboratory-confirmed rotavirus infections. If surveillance data based on routine laboratory testing data are to be used to evaluate the impact of vaccination programmes, it is important to determine how the data are influenced by differences in testing practices, and how these practices are likely to affect the ability of the surveillance data to represent trends in rotavirus disease in the community. We conducted a survey of laboratory testing policies for rotavirus gastroenteritis in England and Wales in 2008. 60% (94/156) of laboratories responded to the survey. 91% of reporting laboratories offered routine testing for rotavirus all year round and 89% of laboratories offered routine rotavirus testing of all stool specimens from children under the age of five years. In 96% of laboratories, rotavirus detection was presently done either by rapid immunochromatographic tests or by enzyme-linked immunosorbent assay. Currently, rotavirus testing policies among laboratories in England and Wales are relatively homogenous. Therefore, surveillance based on laboratory testing data is likely to be representative of rotavirus disease trends in the community in the most frequently affected age groups (children under the age of five years) and could be used to help determine the impact of a rotavirus vaccine.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • Ninety-four of 156 (60%) microbiology laboratories in England and Wales returned completed questionnaires.
    • A k n ow led ge m e n t s 11. Laboratory Reporting To The Health Protection Agency: Guide For Diagnostic
    • Laboratories. London: Health Protection Agency; revised Sept 2008. Available
    • from: http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947381307 12. Velazquez FR, Matson DO, Calva JJ, Guerrero L, Morrow AL, Carter-Campbell
    • infections. N Engl J Med. 1996;335(14):1022-8. 13. Directory of Microbiolog y Laboratories. London: Department of Health; 2007.
    • [Accessed April 2008]. Available from: http://www.dh.gov.uk/en/Publichealth/
    • Patientsafety/Microbiolog yandinfectioncontrol/DH_4135669 14. Kirkwood B. Comparison of means from several groups: analysis of variance.
    • Blackwell Publishing Company; 2003. p. 80-6. 15. Knipe DM, Howley PM, editors. Fields Virology. 4th ed. Philadelphia: Lippincott,
    • Williams and Wilkins; 2001. 16. Standards Unit, Evaluation and Standards Laboratory. Gastroenteritis: Sporadic
    • cases. London: Health Protection Agency; 2007 Jul 27. VSOP 2 Issue 5. Available
    • from: http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop2.pdf 17. Midthun K, Kapikian AZ. Rotavirus vaccines: an overview. Clin Microbiol Rev.
    • 1996;9(3):423-34. 18. Willocks LJ, Wreghitt TG. Laboratory policies on testing for rotavirus affect
    • Commun Dis Public Health. 2000;3(2):115-20.
    • This article was published on 21 May 2009.
    • Citation style for this article: Atchison CJ, Lopman BA, Harris CJ, Tam CC, Iturriza Gómara M, Gray JJ. Clinical laboratory practices for the detection of rotavirus in England and Wales: can surveillance based on routine laboratory testing data be used to evaluate the impact of vaccination?. Euro Surveill. 2009;14(20):pii=19217. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19217 1.
    • Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354(1):23-33.
    • Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354(1):11-22.
    • Centers for Disease Control and Prevention (CDC). Delayed onset and diminished magnitude of rotavirus activity--United States, November 2007-May 2008.
    • MMWR Morb Mortal Wkly Rep. 2008;57(25):697-700.
    • de Oliveira LH, Danovaro-Holliday MC, Matus CR, Andrus JK. Rotavirus vaccine introduction in the Americas: progress and lessons learned. Expert Rev Vaccines. 2008;7(3):345-53.
    • 5. Parashar UD, Alexander JP, Glass RI; Advisory Committee on Immunization
    • Rep. 2006;55(RR-12):1-13.
    • 1st ed. Oxford: Oxford University Press; 1991.
    • Study of infectious intestinal disease in England: rates in the community, presenting to general practice, and reported to national surveillance. The Infectious Intestinal Disease Study Executive. BMJ. 1999;318(7190):1046-50.
    • 8. Jit M, Pebody R, Chen M, Andrews N, Edmunds WJ. Estimating the number
    • Ryan MJ, Ramsay M, Brown D, Gay NJ, Farrington CP, Wall PG. Hospital admissions attributable to rotavirus infection in England and Wales. J Infect Dis. 1996;174 Suppl 1:S12-8.
    • 10. Harris J, Jit M, Cooper D, Edmunds W. Evaluating rotavirus vaccination in
    • 2007 May 16;25(20):3962-70.
  • No related research data.
  • No similar publications.

Share - Bookmark

Download from

Cite this article